Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,041.7
-29.5 (-0.96%)

 

  • STI Straits Times Index
    3,041.7
    -29.5 (-0.96%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,527.9
    -20.6 (-1.33%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,099.1
    -821.6 (-3.30%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,614.0
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    30,323.3
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,076.3
    -56.9 (-0.93%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,423.4M
  • Value: 1,459.2M
  • Rise: 78
  • Fall: 304
  • Unch: 373

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.065-0.008
Sembcorp Marine0.082-0.002
Medi Lifestyle0.033-0.001
Singtel2.440+0.010
CapLand IntCom T2.000-
YZJ Shipbldg SGD1.440-0.040
Intl Cement0.031-0.002
Jiutian Chemical0.077-0.005
VCPlus0.027+0.001
CapitaLandInvest2.950-

World Indices

World Indices
Name Last Change
Nasdaq 14,713.9 -330.1
HSI 24,099.1
HSCEI 8,638.5
Jakarta 6,076.3
Nikkei 225 30,500.0
SSE Comp 3,614.0
Shanghai A 3,787.7
Shanghai B 273.1
KOSPI 3,130.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AFT PHARMACEUTICALS LTD AFT PHARMACEUTICALS
Updated on 20 Sep 2021 (End of trading day)
Last (AUD): 3.890 Change: - High: 3.890 Remarks: -
Change (%): - Low: 3.890
Open 3.890 Yesterday's Close 3.89
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) - Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a 0.06774 Trailing EPS (AUD) e 0.06774 NAV (AUD) b 0.3214
PE a 57.425 Trailing PE f 57.429 Price / NAV b 12.1033
Dividend (AUD) d - Cash In Hand (AUD) g 0.0282 Issued & Paid-up Shares c 104,689,000
Dividend Yield (%) d - Price / Cash In Hand g 137.943 Treasury Shares h -
Beta - 75 Daysi -0.379 R-Squared - 75 Days(%)i 1.82 Market Cap (M) 407.240
Beta - 500 Daysi 0.008 R-Squared - 500 Days (%)i - Enterprise Value (M) 443.108
Piotroski F Score 2 Exchange Code AFP Par Value ( NZD ) n.a.
52 Weeks Volatility (%) 38.13 Free Float (%) 97.2
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 07 Sep 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 20 Jul 2017.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AFT PHARMACEUTICALS LTD ASX 407.240 57.425 57.429 12.1033 -
Industry Pharmaceuticals: Major ASX 144.195 - - 7.6985 -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 554.515 - - 8.8983 -
Local Peer RACE ONCOLOGY LTD ASX 498.253 - - 36.3248 -
Local Peer PYC THERAPEUTICS LIMITED ASX 445.330 - - 8.4848 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 159.876 - - 7.7966 -
Local Peer NOXOPHARM LTD ASX 147.021 - - 3.6068 -
Local Peer CRESO PHARMA LTD ASX 138.179 - - 5.1570 -
Local Peer INVION LTD ASX 83.093 - - 16.6667 -
Local Peer EXOPHARM LTD ASX 72.318 - - 3.8333 -
Local Peer PHARMAXIS ASX 56.721 - - 19.8413 -
Local Peer MEDLAB CLINICAL LIMITED ASX 54.748 - - 3.6117 -
Local Peer PALLA PHARMA LTD ASX 42.907 - - 2.1388 -
Local Peer ONCOSIL MEDICAL LIMITED ASX 34.863 - - 2.9730 -
Other Local Peers ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Global Peer JOHNSON & JOHNSON NYSE 433,701.080 29.475 24.410 6.2331 2.416
Global Peer PFIZER INC NYSE 246,077.624 25.590 18.603 3.5133 3.461
Global Peer ELI LILLY AND COMPANY NYSE 220,109.288 35.538 36.258 34.1552 1.286
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 203,225.382 25.027 22.595 3.7605 2.309
Global Peer ABBVIE INC NYSE 190,378.301 41.786 28.893 15.1466 4.488
Global Peer MERCK & CO INC NYSE 181,448.602 25.675 32.570 5.4499 3.458
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 179,755.310 27.896 25.250 17.1931 1.327
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 172,139.326 53.861 45.648 10.9811 2.089
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 136,237.564 - - 3.7013 3.031
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 122,252.873 8.709 17.654 1.6302 2.764
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), REPLIGEN CORP (NASDAQ), VIATRIS INC (NASDAQ), HANSOH PHARMA (HKEx), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), CUREVAC NV (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), SINOPHARM (HKEx), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REMEGEN-B (HKEx), ALLAKOS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SH PHARMA (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), CMS (HKEx), AKESO-B (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BAIYUNSHAN PH (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), INNOCARE-B (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), CARSGEN-B (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), NEKTAR THERAPEUTICS (NASDAQ), CHINARES PHARMA (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), SIMCERE PHARMA (HKEx), IGM BIOSCIENCES INC (NASDAQ), ERASCA INC (NASDAQ), EVEREST MED-B (HKEx), TRAD CHI MED (HKEx), ADC THERAPEUTICS SA (NYSE), ATEA PHARMACEUTICALS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CSTONE PHARMA-B (HKEx), HENLIUS (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), SSY GROUP (HKEx), ZYMEWORKS INC (NYSE), OCUMENSION-B (HKEx), NURIX THERAPEUTICS INC (NASDAQ), HEPALINK (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GENERATION BIO CO (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), KRONOS BIO INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ICOSAVAX INC (NASDAQ), UNITED LAB (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH-B (HKEx), PHATHOM PHARMACEUTICALS INC (NASDAQ), TONGRENTANGCM (HKEx), KINNATE BIOPHARMA INC (NASDAQ), GH RESEARCH PLC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), SCICLONE PHARMA (HKEx), ANTENGENE-B (HKEx), Kimia Farma Tbk. (IDX), SUTRO BIOPHARMA INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), CKLIFE SCIENCES (HKEx), BEYONDSPRING INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), SHINEWAY PHARM (HKEx), PETIQ INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), ZHAOKE OPHTH-B (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), AC IMMUNE SA (NASDAQ), CLENE INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), RELMADA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), 89BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), PROVENTION BIO INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IGBB (Bursa), CLEARSIDE BIOMEDICAL INC (NASDAQ), ESSA PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), CYBIN INC (NYSE American), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), TOT BIOPHARM-B (HKEx), DURECT CORP (NASDAQ), XOMA CORP (NASDAQ), DAWNRAYS PHARMA (HKEx), OBSEVA SA (NASDAQ), INOZYME PHARMA INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), BSTEAD (Bursa), VINCERX PHARMA INC (NASDAQ), ANNOVIS BIO INC (NYSE American), MUSTANG BIO INC (NASDAQ), PHARMA (Bursa), VECTIVBIO HLDG AG (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), HARROW HEALTH INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), KALEIDO BIOSCIENCES INC (NASDAQ), IMMUNIC INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), FUSEN PHARM (HKEx), OVID THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), ALZAMEND NEURO INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), TRICIDA INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), IP (SET), RENEO PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CH BIOTECH SER (HKEx), TYME TECHNOLOGIES INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), GENPREX INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ZHONGZHIPHARM (HKEx), LANNETT CO INC (NYSE), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), IX Biopharma (SGX), EYENOVIA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), Merck Tbk. (IDX), LYRA THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), CHARMACY PHAR (HKEx), MEDIWOUND LTD (NASDAQ), KOTRA (Bursa), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), SANAI HEALTH GP (HKEx), OCUPHIRE PHARMA INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), GRAYBUG VISION INC (NASDAQ), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), ABVC BIOPHARMA INC (NASDAQ), NC HEALTHCARE (HKEx), VIRPAX PHARMA INC (NASDAQ), NOVA (Bursa), Hyphens Pharma (SGX), BIOHLDG (Bursa), BRICKELL BIOTECH INC (NASDAQ), RENOVORX INC (NASDAQ), MANNATECH INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), MODERN CHI MED (HKEx), NEP INTERLONG (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), SEQLL INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), PURAPHARM (HKEx), AGEX THERAPEUTICS INC (NYSE American), TELIGENT INC NEW (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), DERMATA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), EXTRAWELL PHAR (HKEx), JCT (SET), NLS PHARMACEUTICS LTD (NASDAQ), SUNZEN (Bursa), HOTH THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PASHUN INT'L (HKEx), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.070
-1.77 %
10 Days ---
20 Days --0.340
-8.04 %
Medium Term Return 3 Months --0.320
-7.60 %
6 Months --0.250
-6.04 %
1 Year --0.810
-17.23 %
Long Term Return 2 Years -+1.000
+34.60 %
3 Years -+1.890
+94.50 %
5 Years -+0.990
+34.14 %
Annualised Return Annualised --
+6.05 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 3.640 - 5.250 Change From 1 Year Low +0.250 % Change From 1 Year Low (%) +6.87
Change From 1 Year High -1.360 % Change From 1 Year High (%) -25.90
2 Years Range 2.660 - 5.250 Change From 2 Years Low +1.230 % Change From 2 Years Low (%) +46.24
Change From 2 Years High -1.360 % Change From 2 Years High (%) -25.90
5 Years Range 1.900 - 5.250 Change From 5 Years Low +1.990 % Change From 5 Years Low (%) +104.74
Change From 5 Years High -1.360 % Change From 5 Years High (%) -25.90
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. Its feature brands include Crystaderm, Maxigesic, Coco-Scalp, Maxiclear, Eyecare Hub, and Allergy Hub. It operates through the following geographical segments: Australia, New Zealand, Southeast Asia, and Rest of the World. The Australia segment caters to the Australian market. The New Zealand segment focuses in the head office function, supplier relationships and procurement of stock, and regulatory, marketing, and finance activities of the group. The Southeast Asia segment relates in the sales activities in Brunei, Hong Kong, Malaysia, Philippines, Singapore and Vietnam markets. The Rest of the World segment comprises of out licensing of internet protocol developments to markets in which the firm does not have a presence and the export of products to export markets. The company was founded by Hartley and Marree Atkinson on September 4, 1997 and is headquartered in Auckland, New Zealand.

Historical Price Data

Date Open High Low Close Volume VWAP
20 Sep 2021 3.890 3.890 3.890 3.890 - -
17 Sep 2021 3.890 3.890 3.890 3.890 145 -
16 Sep 2021 4.140 4.140 3.890 3.890 1,003 -
15 Sep 2021 4.150 4.150 4.150 4.150 1,402 -
14 Sep 2021 3.970 3.980 3.960 3.970 4,357 -
13 Sep 2021 3.960 3.960 3.960 3.960 115 -
10 Sep 2021 3.890 3.890 3.890 3.890 - -
09 Sep 2021 3.890 3.890 3.890 3.890 - -
08 Sep 2021 3.890 3.890 3.890 3.890 - -
07 Sep 2021 3.890 3.890 3.890 3.890 - -
06 Sep 2021 3.890 3.890 3.890 3.890 - -
03 Sep 2021 3.920 3.920 3.880 3.890 6,817 -
02 Sep 2021 3.970 3.970 3.970 3.970 - -
01 Sep 2021 4.000 4.000 3.970 3.970 4,959 -
31 Aug 2021 4.040 4.040 4.000 4.000 2,514 -
30 Aug 2021 4.100 4.100 4.100 4.100 2,749 -
27 Aug 2021 4.150 4.150 4.150 4.150 - -
26 Aug 2021 4.150 4.150 4.150 4.150 2,000 -
25 Aug 2021 4.200 4.200 4.100 4.100 2,754 -
24 Aug 2021 4.230 4.230 4.230 4.230 305 -
23 Aug 2021 4.230 4.230 4.230 4.230 125 -
20 Aug 2021 4.230 4.230 4.230 4.230 - -
Summary
Current 2 Weeks
(07 Sep 2021 to 20 Sep 2021)
3.890 4.150 3.890 3.890 7,022 -
Previous 2 Weeks
(24 Aug 2021 to 06 Sep 2021)
4.230 4.230 3.890 3.890 22,098 -
4 Weeks from
(27 Jul 2021 to 23 Aug 2021)
4.330 4.330 3.890 4.230 23,803 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.